Hidden in Plain Sight — Reconsidering the Use of Race Correction in Clinical Algorithms | NEJM; Caution to all researchers and clinicians on the harms of race correction in dx and predictive tools Jesse Ikeme @RWGrantMD 1/5 nejm.org/doi/full/10.10…

Proud to be able to comment on this issue with James Salazar and @RWGrantMD in JAMA Internal Medicine. "Reappraising Medical Syntax—Does Race Belong in the First Line of the Patient History?" ja.ma/3oDyfgH

#MedTwitter I’m excited to share a project near and dear to my ❤️ : Huppert’s Notes! amazon.com/Hupperts-Notes… A thread 🧵...

Welcome back to #AJHTweetorials This week we will discuss academic.oup.com/ajh/article/35… which was the #EditorsChoice from Ernesto Schiffrin Authors Michael Shlipak Michelle Estrella @Ndichu_Muiru Kidney Health Research Collaborative Kidney Research Innovation Hub of San Diego Pranav Garimella 1/

Thank you 2022-2023 Chief Fellows for your hard work and leadership!

Dr Jesse Ikeme UC San Francisco senior research fellow at his nice #KidneyWk poster on uromodulin and CVD outcomes in the SPRINT study Kidney Health Research Collaborative Michelle Estrella Michael Shlipak

Enjoyed writing this NEJM Letter to the Editor with Tom Newman & Michael Kohn UCSF Epidemiology & Biostatistics. And appreciate the authors' response! nejm.org/doi/10.1056/NE…

Celebrating scientific success! Representing UCSF at #NKFClinicals #NKFSCM2024 proud of our current and future fellows! Giselle Peschard Merve Postalcioglu,MD Jesse Ikeme

Celebrating our AMAZING graduating fellows! Cheers to a night filled with fun and laughter!(1/2)

The Association of Plasma and Urine Uromodulin With Cardiovascular Disease in Persons With Hypertension and CKD buff.ly/3WRwkJi (FREE) Jesse Ikeme Pranav Garimella Michelle Estrella Michael Shlipak UCSF Nephrology Kidney Health Research Collaborative #CVD

Fellow UCSF nephrons checking out Jesse Ikeme’s work on plasma and urine UMOD and its association with kidney outcomes in SPRINT.

The effect of sodium-glucose co-transporter-2 inhibitors (SGLT2i) on cardiovascular disease and CKD may be limited if discontinued in persons with CKD. This study found that a substantial proportion of patients experience SGLT2i discontinuation within a year of initiation.

Really proud of my first paper with Carmen A. Peralta, MD, MAS in @CJASN! x.com/CJASN/status/8…

Enjoyed presenting our clopidogrel study at the UC San Francisco Inquiry Symposium! dx.doi.org/10.2215/cjn.00…

Inspired by my colleagues and Dr. Vivek Murthy this morning. Congrats UCSF School of Medicine class of 2017! x.com/UCSFMedicine/s…

Proud Jesse Ikeme on bp lowering and kidney fxn decline #kidneyWk

Had a great time in New Orleans at my first American Society of Nephrology #KidneyWk. So much exciting work being done!

Thrilled to learn I will be staying at UCSF for internal medicine residency! Thank you all who have supported me along the way.

Congrats to my mentor, Carmen A. Peralta, MD, MAS for promotion to full professor! 🎉🎉🎉 I'm lucky to be among the many at UCSF infected by your passion x.com/estrella_khrc/…

Done with med school! Grateful for the village that helped me get here. It's truly an honor to have you behind me.